Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
GAL-021
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
Routes of administration |
IV |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C11H22N6O |
Molar mass | 254.338 g·mol−1 |
3D model (JSmol) | |
|
GAL-021 is a drug related to almitrine which acts as a respiratory stimulant, with its mechanism of action primarily thought to involve blocking the BKCa potassium channel, although secondary mechanisms may also be involved. It was developed by Galleon Pharmaceuticals, and is being tested in clinical trials for potential uses in post-operative care, as well as more generally to counteract the respiratory depression which can be a side effect of opioid analgesic drugs.
See also
Other respiratory system products (R07)
| |
---|---|
Lung surfactants | |
Respiratory stimulants | |
5-HT4 receptor agonists | |
Other agents for treating respiratory depression |